In a report published Wednesday, Canaccord Genuity reiterated its Buy rating and $11.00 price target on Raptor Pharmaceutical (NASDAQ:

). Canaccord Genuity noted, “Reiterate BUY, $11 target on high chance of PROCYSBI H1/13 US and 2014 EU approval/launch. We expect PROCYSBI to be approved in the US (March 30 PDUFA) and EU, with H1/13 and 2014 launches, respectively. We predict manageable payor pushback on premium orphan pricing and quick adoption. Our $11 target is based on a pNPV analysis.” Raptor Pharmaceutical closed on Monday at $5.39.